MYCN and neuroblastoma: To assess whether the cytotoxic effects of Regorafenib are consistent across neuroblastoma subtypes, we examined its impact on both MYCN-amplified (SK-N-DZ) and MYCN non-amplified (SK-N-SH) cell lines.